IFPMA widens requirements for clinical trial disclosure
This article was originally published in SRA
Executive Summary
Member companies of the International Federation of Pharmaceutical Manufacturers and Associations must now make publicly available the details of all confirmatory and exploratory efficacy clinical trials - in addition to most other trials - under an updated version of the federation’s Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases1.